FrancophonIA/ELRC3.0 huggingface dataset:
English: If clinical symptoms consistent with acute viral infection are present and recent (< 1 month) exposures to HIV-1 are suspected, use of Emtricitabine/Tenofovir disoproxil Krka should be delayed for at least one month and HIV-1 status reconfirmed before starting Emtricitabine/Tenofovir disoproxil Krka for pre-exposure prophylaxis.
Croatian: Ako su prisutni klinički simptomi sukladni akutnoj virusnoj infekciji, a sumnja se na nedavnu (< 1 mjeseca) izloženost virusu HIV-1, primjenu lijeka Emtricitabine/Tenofovir disoproxil Krka treba odgoditi za najmanje mjesec dana i ponovno provjeriti HIV-1 status prije početka primjene lijeka Emtricitabine/Tenofovir disoproxil Krka za predekspozicijsku profilaksu.
English: Herpes virus antiviral agents Famciclovir/Emtricitabine
Croatian: Antivirusni lijekovi za herpes virus Famciklovir/Emtricitabin
English: The safety and efficacy of emtricitabine/tenofovir in children under the age of 12 years have not been established.
Croatian: Sigurnost i djelotvornost emtricitabina/tenofovira u djece mlađe od 12 godina nisu ustanovljene.
English: In some patients with advanced liver disease or cirrhosis, stopping treatment is not recommended as this may lead to worsening of your hepatitis, which may be life-threatening.
Croatian: U nekih se bolesnika s uznapredovalom bolešću jetre ili cirozom jetre ne preporučuje prekid liječenja, jer to može dovesti do pogoršanja hepatitisa, koje može biti životno ugrožavajuće.
English: Steady-state pharmacokinetics of tenofovir were evaluated in 8 HIV-1 infected adolescent patients (aged 12 to < 18 years) with body weight ≥ 35 kg and in 23 HIV1 infected children aged 2 to < 12 years.
Croatian: Farmakokinetika tenofovira u stanju dinamičke ravnoteže bila je procijenjena u 8 adolescentnih bolesnika zaraženih virusom HIV-1 (u dobi od 12 do < 18 godina) tjelesne težine ≥ 35 kg i u 23 djece zaražene virusom HIV-1 u dobi od 2 do < 12 godina.
English: Key Couple Characteristics, N (%) or Median (Q1, Q3) Married to study partner
Croatian: Ključne značajke para, N (%) ili medijan (Q1, Q3)
English: Moreover, the reversibility of renal toxicity after cessation of tenofovir disoproxil for treatment of HIV-1 or after cessation of emtricitabine/tenofovir for preexposure prophylaxis cannot be fully ascertained.
Croatian: Štoviše, reverzibilnost toksičnosti za bubrege nakon prestanka primjene tenofovirdizoproksila za liječenje infekcije virusom HIV-1 ili nakon prestanka primjene emtricitabina/tenofovira za predekspozicijsku profilaksu ne može se sa sigurnošću utvrditi.
English: HIV-1 infected patients receiving Emtricitabine/Tenofovir disoproxil Krka or any other antiretroviral therapy may continue to develop opportunistic infections and other complications of HIV infection, and therefore should remain under close clinical observation by physicians experienced in the treatment of patients with HIV associated diseases.
Croatian: Bolesnici zaraženi virusom HIV-1 koji primaju lijek Emtricitabine/Tenofovir disoproxil Krka ili neku drugu antiretrovirusnu terapiju mogu i dalje razvijati oportunističke infekcije i druge komplikacije infekcije HIV-om pa stoga trebaju biti pod pažljivim kliničkim nadzorom liječnika s iskustvom u liječenju bolesnika s bolestima povezanima s HIV-om.
English: Renal clearance has been estimated to be approximately 210 mL/min, which is in excess of the glomerular filtration rate.
Croatian: Procijenjeno je da je bubrežni klirens oko 210 mL/min, što prelazi brzinu glomerularne filtracije.
English: Tests may also show: low white blood cell count (a reduced white blood cell count can make you more prone to infection) increased triglycerides (fatty acids), bile or sugar in the blood liver and pancreas problems
Croatian: Pretrage mogu također pokazati: - nizak broj bijelih krvnih stanica (zbog smanjenog broja bijelih krvnih stanica možete postati skloniji infekcijama) - povišene trigliceride (masne kiseline), bilirubin (žučna boja) ili šećer u krvi - tegobe s jetrom ili gušteračom
English: However, in some HIV-1 infected patients, declines in creatinine clearance did not completely resolve despite tenofovir disoproxil discontinuation.
Croatian: Međutim, u nekih se bolesnika zaraženih virusom HIV-1 smanjenje klirensa kreatinina nije potpuno povuklo usprkos prekidu terapije tenofovirdizoproksila.
English: People who do have HIV must take Emtricitabine/Tenofovir disoproxil Krka in combination with other drugs.
Croatian: Osobe koje imaju HIV moraju uzimati Emtricitabine/Tenofovir disoproxil Krka u kombinaciji s drugim lijekovima.
English: Some patients taking combination antiretroviral medicines such as emtricitabine/tenofovir disoproxil may develop a bone disease called osteonecrosis (death of bone tissue caused by loss of blood supply to the bone).
Croatian: U nekih se bolesnika koji uzimaju kombiniranu antiretrovirusnu terapiju kao što je emtricitabin/tenofovirdizoproksil može razviti koštana bolest koja se naziva osteonekroza (odumiranje koštanog tkiva uzrokovano gubitkom dovoda krvi u kost).
English: When using emtricitabine/tenofovir for pre-exposure prophylaxis individuals should be reassessed at each visit to ascertain whether they remain at high risk of HIV-1 infection.
Croatian: Kada se emtricitabin/tenofovir primjenjuje za predekspozicijsku profilaksu, svaku bi osobu trebalo ponovno procijeniti na svakom kontrolnom pregledu kako bi se potvrdilo je li ona i dalje pod visokim rizikom od infekcije virusom HIV-1.
English: Immune Reactivation Syndrome: In HIV infected patients with severe immune deficiency at the time of initiation of CART, an inflammatory reaction to asymptomatic or residual opportunistic infections may arise.
Croatian: Sindrom imunološke reaktivacije: U bolesnika zaraženih HIV-om s teškom imunodeficijencijom u vrijeme početka CART-a može nastati upalna reakcija na asimptomatske ili rezidualne oportunističke infekcije.
English: If you accidentally take more than the recommended dose of Emtricitabine/Tenofovir disoproxil Krka, contact your doctor or nearest emergency department for advice.
Croatian: Ako slučajno uzmete veću dozu lijeka Emtricitabine/Tenofovir disoproxil Krka od preporučene, obratite se svom liječniku ili najbližoj hitnoj službi.
English: If you have hepatitis B, it is especially important not to stop your Emtricitabine/Tenofovir disoproxil Krka treatment without talking to your doctor first.
Croatian: - Ako imate i hepatitis B, naročito je važno da se ne prestanete liječiti lijekom Emtricitabine/Tenofovir disoproxil Krka, a da prije toga niste razgovarali s liječnikom.
English: HIV-1 expressing three or more thymidine analogue associated mutations (TAMs) that included either the M41L or L210W reverse transcriptase mutation showed reduced susceptibility to tenofovir disoproxil.
Croatian: HIV-1 koji je eksprimirao tri ili više mutacija povezanih s analogom timidina (engl. thymidine-analoque associated mutations, TAMs), koje su uključivale bilo M41L ili L210W mutaciju reverzne transkriptaze, pokazao je smanjenu osjetljivost na tenofovirdizoproksil.
English: Table 3: Tabulated summary of adverse reactions associated with tenofovir disoproxil and emtricitabine based on clinical study and post-marketing experience
Croatian: Tablica 3: Tablični prikaz nuspojava povezanih s tenofovirdizoproksilom i emtricitabinom na temelju kliničkih ispitivanja i iskustva nakon stavljanja u promet
English: Emtricitabine/Tenofovir disoproxil Krka should only be used for pre-exposure prophylaxis as part of an overall HIV-1 infection prevention strategy including the use of other HIV-1 prevention measures (e.g. consistent and correct condom use, knowledge of HIV-1 status, regular testing for other sexually transmitted infections).
Croatian: Emtricitabine/Tenofovir disoproxil Krka se smije primjenjivati za predekspozicijsku profilaksu samo u sklopu ukupne strategije sprječavanja infekcije virusom HIV-1, koja uključuje i primjenu drugih mjera sprječavanja infekcije virusom HIV-1 (npr. dosljedna i ispravna uporaba kondoma, poznavanje HIV-1 statusa, redovito testiranje na druge spolno prenosive infekcije).
English: Tests may also show: decreases in phosphate in the blood increased creatine kinase
Croatian: Pretrage također mogu pokazati: - smanjenu razinu fosfata u krvi - povišenu kreatin kinazu
English: It is important not to stop taking Emtricitabine/Tenofovir disoproxil Krka without talking to your doctor: see section 3, Do not stop taking Emtricitabine/Tenofovir disoproxil Krka.
Croatian: Važno je da ne prestanete uzimati Emtricitabine/Tenofovir disoproxil Krka bez prethodnog razgovora s liječnikom; pogledajte dio 3, Nemojte prestati uzmati Emtricitabine/ Tenofovir disoproxil Krka.
English: % difference (95%CI)
Croatian: % razlike (95%CI)
English: Bone problems (sometimes resulting in fractures) may also occur due to damage to kidney tubule cells (see section 4, Possible side effects).
Croatian: Tegobe s kostima (koje ponekad dovode do prijeloma) mogu se također pojaviti zbog oštećenja stanica bubrežnih kanalića (vidjeti dio 4, Moguće nuspojave).
English: HIV-1 infected patients with pre-existing liver dysfunction, including chronic active hepatitis, have an increased frequency of liver function abnormalities during combination antiretroviral therapy (CART) and should be monitored according to standard practice.
Croatian: Bolesnici zaraženi virusom HIV-1 i s otprije postojećim poremećajem funkcije jetre, uključujući kronični aktivni hepatitis, imaju povećanu učestalost abnormalnosti funkcije jetre tijekom kombinirane antiretrovirusne terapije (engl. combination antiretroviral therapy, CART), pa ih treba pratiti u skladu sa standardnom praksom.
English: The degree of renal impairment was defined according to baseline creatinine clearance (CrCl) (normal renal function when CrCl > 80 mL/min; mild impairment with CrCl = 50-79 mL/min; moderate impairment with CrCl = 30-49 mL/min and severe impairment with CrCl = 10-29 mL/min).
Croatian: Stupanj oštećenja funkcije bubrega definiran je prema početnom klirensu kreatinina (CrCl) (normalna funkcija bubrega kada je CrCl > 80 mL/min; blago oštećenje uz CrCl = 50-79 mL/min; umjereno oštećenje uz CrCl = 30-49 mL/min i teško oštećenje uz CrCl = 10-29 mL/min).
English: Relative risk reduction calculated for mITT based on incident seroconversion, ie, occurring post-baseline through first posttreatment visit (approximately 1 month after last study drug dispensation).
Croatian: Smanjenje relativnog rizika izračunato za mITT na temelju incidentne serokonverzije, tj. one koja je nastupila u razdoblju nakon početka ispitivanja do prve kontrole nakon liječenja (približno 1 mjesec nakon zadnjeg izdavanja ispitivanog lijeka).
English: Damage to kidney tubule cells may be associated with breakdown of muscle, softening of the bones (with bone pain and sometimes resulting in fractures), muscle pain, muscle weakness and decreases in potassium or phosphate in the blood.
Croatian: Oštećenje stanica bubrežnih kanalića može biti povezano s propadanjem mišića, omekšavanjem kosti (uz bol u kostima i ponekad posljedičnim prijelomima), bolom u mišićima, mišićnom slabošću i sniženjem razine kalija ili fosfata u krvi.
English: Emtricitabine/tenofovir disoproxil (n = 1251)
Croatian: Emtricitabin/ tenofovirdizoproksil (n = 1251)
English: Relative risk reduction calculated for mITT cohort based on incident (post-baseline) seroconversion.
Croatian: Smanjenje relativnog rizika izračunato za mITT kohortu na temelju incidentne serokonverzije (nakon početka ispitivanja).
English: HIV-1 RNA < 50 copies/mL (TLOVR)
Croatian: HIV-1 RNK < 50 kopija/mL (TLOVR)
English: - Genotypic resistance to efavirenz, predominantly the K103N mutation, developed in virus from 13/19 (68%) patients in the emtricitabine/tenofovir disoproxil /efavirenz group and in virus from 21/29 (72%) patients in the comparative group.
Croatian: Genotipska rezistencija na efavirenz, pretežno mutacija K103N, razvila se kod virusa u 13/19 (68%) bolesnika iz skupine emtricitabin/tenofovirdizoproksil/efavirenz te kod virusa u 21/29 (72%) bolesnika u usporednoj skupini.
English: A subgroup of patients with baseline creatinine clearance between 50 and 60 mL/min, receiving once daily dosing, had a 2-4-fold increase in tenofovir exposure and worsening renal function.
Croatian: Podskupina bolesnika s početnim klirensom kreatinina između 50 i 60 mL/min, koji su primali dozu jedanput na dan, imala je 2-4 puta povećanu izloženost tenofoviru i pogoršanje funkcije bubrega.
English: Efficacy was strongly correlated with adherence as assessed by detection of plasma or intracellular drug levels and was higher among substudy participants who received active adherence counselling and as show in Table 10.
Croatian: Djelotvornost je snažno korelirala s pridržavanjem terapije, kako je procijenjeno otkrivanjem razine lijeka u plazmi ili unutar stanica i bila je viša među ispitanicima u podispitivanju koji su dobili aktivno savjetovanje o pridržavanju terapije, kako je prikazano u Tablici 10.
English: In subjects with end-stage renal disease (ESRD) requiring haemodialysis, between dialysis drug exposures substantially increased over 72 hours to 53 (19%) µg•h/mL of emtricitabine, and over 48 hours to 42,857 (29%) ng•h/mL of tenofovir.
Croatian: U ispitanika s bubrežnom bolešću u završnoj fazi (ESRD, end-stage renal disease) koji trebaju hemodijalizu, izloženost lijeku između dijaliza znatno se povećala tijekom 72 sata na 53 (19%) µg•h/mL emtricitabina, a tijekom 48 sati na 42 857 (29%) ng•h/mL tenofovira.
English: Therefore, a careful benefitrisk assessment is needed when Emtricitabine/Tenofovir disoproxil Krka is used in patients with creatinine clearance < 60 mL/min, and renal function should be closely monitored.
Croatian: Stoga je potrebna oprezna procjena odnosa koristi i rizika kad se Emtricitabine/Tenofovir disoproxil Krka primjenjuje u bolesnika s klirensom kreatinina < 60 mL/min i treba pažljivo pratiti funkciju bubrega.
English: At 48 weeks, 70% and 64% of patients demonstrated HIV-1 RNA < 50 copies/mL with the once and twice daily regimens of lopinavir/ritonavir, respectively.
Croatian: U 48. tjednu je 70% odnosno 64% bolesnika pokazalo HIV-1 RNK < 50 kopija/mL uz režim doziranja lopinavira/ritonavira jedanput odnosno dvaput na dan.
English: Pre-exposure prophylaxis: The iPrEx study (CO-US-104-0288) evaluated emtricitabine/tenofovir disoproxil or placebo in 2,499 HIV-uninfected men (or transgender women) who have sex with men and who were considered at high risk for HIV infection.
Croatian: Predekspozicijska profilaksa: Ispitivanje iPrEx (CO-US-104-0288) procijenilo je emtricitabin/tenofovirdizoproksil ili placebo u 2499 muškaraca (ili transrodnih žena) koji nisu bili zaraženi HIV-om koji su imali spolne odnose s muškarcima i za koje se smatralo da imaju visok rizik od infekcije HIV-om.
English: Limited clinical experience in patients co-infected with HIV and HBV suggests that treatment with emtricitabine or tenofovir disoproxil in antiretroviral combination therapy to control HIV infection results in a reduction in HBV DNA (3 log10 reduction or 4 to 5 log10 reduction, respectively) (see section 4.4).
Croatian: Ograničeno kliničko iskustvo u bolesnika koji su bili istovremeno zaraženi s HIV-om i HBV-om, navodi na zaključak da liječenje s emtricitabinom ili tenofovirdioproksilom u kombiniranoj antiretrovirusnoj terapiji, u cilju kontroliranja infekcije HIV-om, rezultira smanjenjem HBV DNK (smanjenje od 3 log10 odnosno smanjenje od 4 do 5 log10) (vidjeti dio 4.4).
English: Cmax: ↓ 19% (↓ 40 to ↑ 10) GS-331007
Croatian: Cmax: ↓ 19% (↓ 40 do ↑ 10) GS-331007
English: In a 144-week controlled clinical study that compared tenofovir disoproxil with stavudine in combination with lamivudine and efavirenz in antiretroviral-naïve patients, small decreases in bone mineral density (BMD) of the hip and spine were observed in both treatment groups.
Croatian: U kontroliranom kliničkom ispitivanju koje je trajalo 144. tjedna i u kojemu je tenofovirdizoproksil uspoređivan sa stavudinom u kombinaciji s lamivudinom i efavirenzom u bolesnika koji prethodno nisu bili liječeni antiretrovirusnim lijekovima, u obje su liječene skupine zapažena mala smanjenja mineralne gustoće kosti (engl. mineral bone density, BMD) kuka i kralježnice.
English: The frequency category was estimated from a statistical calculation based on the total number of patients exposed to emtricitabine in randomised controlled clinical studies (n = 1,563) or tenofovir disoproxil in randomised controlled clinical studies and the expanded access program (n = 7,319).
Croatian: Kategorija učestalosti procijenjena je pomoću statističkog proračuna na temelju ukupnog broja bolesnika izloženih emtricitabinu u randomiziranim kontroliranim kliničkim ispitivanjima (n = 1563) ili tenofovirdizoproksilu u randomiziranim kontroliranim kliničkim ispitivanjima i programu proširenog pristupa liječenju (n = 7319).
English: Taking Emtricitabine/Tenofovir disoproxil Krka with other medicines that can damage your kidneys: it is especially important to tell your doctor if you are taking any of these medicines, including aminoglycosides (for bacterial infection) amphotericin B (for fungal infection) foscarnet (for viral infection) ganciclovir (for viral infection) pentamidine (for infections) vancomycin (for bacterial infection)
Croatian: Uzimanje lijeka Emtricitabine/Tenofovir disoproxil Krka s drugim lijekovima koji Vam mogu oštetiti bubrege: posebno je važno da liječnika obavijestite ako uzimate neki od tih lijekova, koji uključuju: - aminoglikozide (za bakterijsku infekciju) - amfotericin B (za gljivičnu infekciju) - foskarnet (za virusnu infekciju) - ganciklovir (za virusnu infekciju) - pentamidin (za infekcije) - vankomicin (za bakterijsku infekciju) - interleukin-2 (za liječenje raka) - cidofovir (za virusnu infekciju) - nesteroidne antiinflamatorne (protuupalne) lijekove (NSAIL, za ublažavanje boli u kostima ili mišićima)
English: Renal function (creatinine clearance and serum phosphate) should be evaluated prior to initiating emtricitabine/tenofovir for treatment of HIV-1 or for pre-exposure prophylaxis, and should be monitored during use as in adults (see above).
Croatian: Funkciju bubrega (klirens kreatinina i fosfate u serumu) treba procijeniti prije uvođenja emtricitabina/tenofovira za liječenje infekcije virusom HIV-a ili predekspozicijske profilakse i treba je pratiti tijekom primjene kao i u odraslih osoba (vidjeti gore).
English: HIV-1 RNA < 400 copies/mL (TLOVR)
Croatian: HIV-1 RNK < 400 kopija/mL (TLOVR)
English: Relative risk reduction calculated on incident (post-baseline) seroconversion from the double-blind treatment period and through the 8-week follow-up period.
Croatian: Smanjenje relativnog rizika izračunato po incidentnoj serokonverziji (nakon početka ispitivanja) iz dvostruko slijepog razdoblja liječenja i tijekom 8-tjednog razdoblja praćenja.
English: Patients infected with HIV who also have liver disease (including chronic hepatitis B or C), who are treated with antiretrovirals, have a higher risk of severe and potentially fatal liver complications.
Croatian: Bolesnici zaraženi HIV-om koji imaju i bolest jetre (uključujući kronični hepatitis B ili C), koji se liječe antiretrovirusnim lijekovima, izloženi su većem riziku od teških i potencijalno smrtonosnih jetrenih komplikacija.
English: Exacerbations of hepatitis after discontinuation of treatment: In HBV infected patients, clinical and laboratory evidence of hepatitis have occurred after discontinuation of treatment (see section 4.4).
Croatian: Egzacerbacije hepatitisa nakon prekida liječenja: U bolesnika zaraženih HBV-om, nakon prekida liječenja hepatitis se mogao klinički i laboratorijski dokazati (vidjeti dio 4.4).
English: Patients with HIV-1 harbouring mutations
Croatian: Bolesnici s virusom HIV-1 koji nosi mutaciju
English: Table 4: 48- and 144-week efficacy data from study GS-01-934 in which emtricitabine, tenofovir disoproxil and efavirenz were administered to antiretroviral-naïve patients with HIV-1 infection
Croatian: Tablica 4: Podaci o djelotvornosti u 48. i 144. tjednu ispitivanja GS-01-934 u kojem su emtricitabin, tenofovirdizoproksil i efavirenz davani bolesnicima s HIV-1 infekcijom, koji prije nisu bili liječeni antiretrovirusnom terapijom
English: The apparent clearance of tenofovir averaged approximately 307 mL/min.
Croatian: Prividni klirens tenofovira je u prosjeku iznosio oko 307 mL/min.
English: Do not take Emtricitabine/Tenofovir disoproxil Krka to reduce your risk unless you are confirmed to be HIV negative.
Croatian: Nemojte uzimati lijek Emtricitabine/Tenofovir disoproxil Krka da biste smanjili svoj rizik osim ako nije potvrđeno da ste HIV negativni.
English: - The M184V/I mutation developed in 2/19 (10.5%) isolates analysed from patients in the emtricitabine/tenofovir disoproxil /efavirenz group and in 10/29 (34.5%) isolates analysed from the lamivudine/zidovudine/efavirenz group (p-value < 0.05, Fisher's Exact test comparing the emtricitabine+tenofovir disoproxil group to the lamivudine/zidovudine group among all patients).
Croatian: Mutacija M184V/I razvila se u 2/19 (10,5%) izolata analiziranih u bolesnika iz skupine emtricitabin/tenofovirdizoproksil/efavirenz, te u 10/29 (34,5%) izolata analiziranih u bolesnika iz skupine lamivudin/zidovudin/efavirenz (p-vrijednost < 0,05, Fisherov egzaktni test koji uspoređuje skupinu emtricitabin+tenofovirdizoproksil sa skupinom lamivudin/ zidovudin među svim bolesnicima).
English: If you take more Emtricitabine/Tenofovir disoproxil Krka than you should
Croatian: Ako uzmete više Emtricitabine/Tenofovir disoproxil Krka nego što ste trebali
English: Hepatitis C virus (HCV) antiviral agents
Croatian: Antivirusni lijekovi za virus hepatitisa C (HCV)
English: Severe renal impairment (CrCl < 30 mL/min) and haemodialysis patients
Croatian: Teško oštećenje funkcije bubrega (CrCl <30mL/min) i bolesnici na hemodijalizi
English: Taking Emtricitabine/Tenofovir disoproxil Krka with other medicines containing didanosine (for treatment of HIV infection): Taking Emtricitabine/Tenofovir disoproxil Krka with other antiviral medicines that contain didanosine can raise the levels of didanosine in your blood and may reduce CD4 cell counts.
Croatian: Uzimanje lijeka Emtricitabine/Tenofovir disoproxil Krka s drugim lijekovima koji sadrže didanozin (za liječenje infekcije virusom HIV-a): Uzimanjem lijeka Emtricitabine/Tenofovir disoproxil Krka s drugim antivirusnim lijekovima koji sadrže didanozin može Vam se povećati razina didanozina u krvi i smanjiti broj CD4 stanica.
English: Renal safety with emtricitabine/tenofovir disoproxil has only been studied to a very limited degree in HIV-1 infected patients with impaired renal function (creatinine clearance < 80 mL/min).
Croatian: Sigurnost bubrega uz emtricitabin/tenofovirdizoproksil istraživana je samo u vrlo ograničenoj mjeri u bolesnika zaraženih s HIV-1 s oštećenjem funkcije bubrega (klirens kreatinina < 80 mL/min).
English: 30 film-coated tablets: EU/1/16/1151/002 90 (3 x 30) film-coated tablets: EU/1/16/1151/004
Croatian: 30 filmom obloženih tableta: EU/1/16/1151/002 90 (3 x 30) filmom obloženih tableta: EU/1/16/1151/004
English: tenofovir diphosphate competitively inhibit HIV-1 reverse transcriptase, resulting in DNA chain termination.
Croatian: Emtricitabintrifosfat i tenofovirdifosfat kompetitivno inhibiraju HIV-1 reverznu transkriptazu, što rezultira prekidom lanca DNK.
English: You do not need to take another tablet if you were sick more than 1 hour after taking Emtricitabine/Tenofovir disoproxil Krka.
Croatian: Drugu tabletu ne trebate uzimati ako ste povraćali nakon što je prošlo više od 1 sata po uzimanju lijeka Emtricitabine/Tenofovir disoproxil Krka.
English: However, individuals should be informed that dizziness has been reported during treatment with both emtricitabine and tenofovir disoproxil.
Croatian: No, osobe je potrebno obavijestiti da je zabilježena omaglica tijekom liječenja i emtricitabinom i tenofovirdizoproksilom.